Citigroup Downgrades Aerie Pharmaceuticals to Neutral

Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.

byBenzinga Newsdesk

August 29, 2022

1 minute read

Citigroup analyst Yigal Nochomovitz downgrades Aerie Pharmaceuticals (NASDAQ:AERI) from Buy to Neutral.

$1000 Invested In Synopsys 5 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 16, 3:43 PM

Synopsys (NASDAQ:SNPS) has outperformed the market over the past 5 years by 25.55% on an annualized basis producing an average annual return of 37.58%. Currently, Synopsys has a market capitalization of $58.79 billion.

SNPS

News

Katapult Reports Booked Gross Originations Of $40.4M From Oct. 1 To Nov. 30, 2021

By Benzinga Newsdesk

December 1, 5:13 PM

Katapult Holdings, Inc. (“Katapult” or the “Company”) (NASDAQ:KPLT), an e-commerce focused financial technology company, today provided an interim update on its quarter-to-date Gross Originations.

KPLT

Oncolytics Biotech Announces Publication Of Preclinical Data Demonstrating The Synergistic Anti-Cancer Activity Of Pelareorep Combined With CAR T Cell Therapy In Solid Tumors In Science Translational Medicine

By Benzinga Newsdesk

April 14, 7:10 AM

- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors - Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a

ONCY